PHARVARIS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.81 USD | +1.88% |
|
-11.06% | -40.07% |
| Jun. 04 | Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses | CI |
| May. 09 | Wedbush Adjusts Pharvaris' Price Target to $31 From $35, Maintains Outperform Rating | MT |
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 831M 905M |
|---|---|---|---|---|---|
| Net income 2024 * | -122M -133M | Net income 2025 * | -139M -151M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 269M 293M | Net cash position 2025 * | 132M 143M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-6.44
x | P/E ratio 2025 * |
-6.15
x | Employees | 83 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 61% |
More Fundamentals
* Assessed data
More news
Latest transcript on Pharvaris N.V.
More recommendations
More press releases
| 1 day | +1.88% | ||
| 1 week | -13.35% | ||
| Current month | -11.34% | ||
| 1 month | -25.62% | ||
| 3 months | -30.59% | ||
| 6 months | -19.76% | ||
| Current year | -40.07% |
1 week
15.84
19.70
1 month
15.8424.11
Current year
15.8433.00
1 year
8.2033.00
3 years
1.7733.00
5 years
1.7742.86
10 years
1.7742.86
| Managers | Title | Age | Since |
|---|---|---|---|
Anne Lesage
FOU | Founder | 63 | 15-09-29 |
| Founder | 65 | 15-09-29 | |
Stefan Abele
CTO | Chief Tech/Sci/R&D Officer | 55 | Nov. 14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Founder | 65 | 15-09-29 | |
David Meeker
CHM | Chairman | 69 | 20-12-31 |
Robert Glassman
BRD | Director/Board Member | 62 | 20-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-06 | 16.81 | +1.88% | 50,523 |
| 24-06-05 | 16.5 | -1.61% | 51,523 |
| 24-06-04 | 16.77 | -5.31% | 40,060 |
| 24-06-03 | 17.71 | -6.59% | 55,871 |
| 24-05-31 | 18.96 | +0.32% | 9,427 |
Delayed Quote Nasdaq, June 06, 2024 at 04:00 pm EDT
More quotes
Pharvaris BV is a Switzerland-based clinical-stage company. The activity of the Company focuses on producing oral bradykinin B2-receptor antagonists and is advancing new alternatives to injected therapies for all sub-types of hereditary angioedema (HAE).
Calendar
2024-07-25
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
15.45
EUR
Average target price
30.79
EUR
Spread / Average Target
+99.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.07% | 888M | |
| +55.55% | 59.34B | |
| +43.17% | 40.24B | |
| -4.71% | 39.88B | |
| -5.56% | 28.55B | |
| +13.76% | 27.26B | |
| -22.00% | 19.23B | |
| +31.50% | 12.61B | |
| +2.16% | 12.49B | |
| +25.70% | 12.28B |
- Stock Market
- Equities
- PHVS Stock
